Advisor Group Inc. lessened its position in shares of Iradimed Corp (NASDAQ:IRMD) by 23.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,250 shares of the medical equipment provider’s stock after selling 700 shares during the quarter. Advisor Group Inc.’s holdings in Iradimed were worth $55,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Ruggie Capital Group acquired a new stake in Iradimed during the fourth quarter valued at $34,000. Nkcfo LLC acquired a new stake in Iradimed during the fourth quarter valued at $87,000. Teachers Advisors LLC acquired a new stake in Iradimed during the third quarter valued at $261,000. GSA Capital Partners LLP acquired a new stake in Iradimed during the third quarter valued at $382,000. Finally, Dupont Capital Management Corp acquired a new stake in Iradimed during the fourth quarter valued at $364,000. Institutional investors own 21.26% of the company’s stock.

IRMD opened at $27.68 on Tuesday. The firm has a market cap of $306.59 million, a price-to-earnings ratio of 64.37 and a beta of 1.80. Iradimed Corp has a 52-week low of $14.75 and a 52-week high of $38.78.

Iradimed (NASDAQ:IRMD) last posted its quarterly earnings data on Wednesday, February 6th. The medical equipment provider reported $0.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.01. The business had revenue of $8.34 million for the quarter, compared to the consensus estimate of $8.19 million. Iradimed had a net margin of 20.71% and a return on equity of 13.78%. As a group, equities research analysts predict that Iradimed Corp will post 0.62 EPS for the current year.

Several research firms have issued reports on IRMD. ValuEngine downgraded shares of Iradimed from a “buy” rating to a “hold” rating in a report on Tuesday, December 25th. Zacks Investment Research downgraded shares of Iradimed from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, BidaskClub raised shares of Iradimed from a “hold” rating to a “buy” rating in a report on Friday, February 8th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $33.00.

In other Iradimed news, Director Monty K. Allen sold 10,000 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $25.39, for a total transaction of $253,900.00. Following the transaction, the director now directly owns 33,663 shares of the company’s stock, valued at $854,703.57. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Steven M. Nardi sold 1,418 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $26.07, for a total transaction of $36,967.26. Following the transaction, the vice president now directly owns 3,228 shares in the company, valued at $84,153.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,615 shares of company stock worth $2,606,807. Insiders own 61.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2019/04/16/advisor-group-inc-has-55000-position-in-iradimed-corp-irmd.html.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Featured Story: What is the float in trading stocks?

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iradimed Corp (NASDAQ:IRMD).

Institutional Ownership by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.